Obigen Pharma Inc.

TPEX:7876 Stock Report

Market Cap: NT$3.8b

Obigen Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Patricia Chou

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.4yrs
CEO ownershipn/a
Management average tenure2.7yrs
Board average tenureless than a year

Recent management updates

Recent updates

CEO

Patricia Chou (58 yo)

1.4yrs
Tenure

Ms. Peifen Chou, also known as Patricia, is Representative Director of Obigen Pharma Inc. from March 18, 2024 and serves as its Chief Executive Officer since February 18, 2025. Ms. Chou served as Vice Pres...

Leadership Team

NamePositionTenureCompensationOwnership
Peifen Chou
CEO & Representative Director1.4yrsno datano data
Changmin Wu
Finance Directorless than a yearno datano data
Sheila Chuang
Head of Accountingno datano datano data
Rennie Jiang
Administrative Director2.6yrsno datano data
Raul Tsau
Director of Production & Chief of Staffno datano datano data
Cheng Ru Cai
Head of Audit2.8yrsno datano data
Samuel Shen
Plant Manager of API Plant5.3yrsno datano data
Ken Wang
Research & Development Managerno datano datano data
Danny Ho
Plant Manager of Drug Product Plant4.8yrsno datano data
2.7yrs
Average Tenure

Experienced Management: 7876's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peifen Chou
CEO & Representative Director2.3yrsno datano data
Jo Shen
Representative Director5.3yrsno data0.030%
NT$ 1.2m
Yeong-Fang Chiang
Chairmanless than a yearno datano data
Chen-Wu Chang
Independent Directorless than a yearno datano data
Chung-Yao Yin
Representative Director5.3yrsno datano data
James Liu
Independent Directorless than a yearno datano data
Sung-Po Chen
Independent Directorless than a yearno datano data
0.5yrs
Average Tenure
58yo
Average Age

Experienced Board: 7876's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/22 21:17
End of Day Share Price 2026/07/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Obigen Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.